Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2024-06-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于为全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Nanjing Yaoshi Technology Co., Ltd. regarding the progress of providing guarantees for its wholly-owned subsidiary. It details the guarantee amount, the parties involved, financial indicators of the subsidiary, and the guarantee contract's main content. The document is an update on financing-related activities, specifically about guarantees provided for loans. It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it concerns financing guarantees and related contractual progress.
2024-06-17 Chinese
关于药石转债恢复转股的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of conversion rights for a convertible bond (药石转债) starting from June 14, 2024. It references the company's equity distribution plan and relevant bond issuance documents but does not contain financial statements or detailed financial data. The length is only 498 characters, indicating it is a brief notice rather than a full report. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about bond conversion resumption, not a full financial report or capital/financing update per se.
2024-06-13 Chinese
南京药石科技股份有限公司向不特定对象发行可转换公司债券受托管理事务报告（2023年度）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '受托管理事务报告（2023年度）' which translates to 'Trustee Management Affairs Report (2023 Annual)'. It concerns the issuance and management of convertible bonds by 南京药石科技股份有限公司 (Pharmablock Sciences (Nanjing) Inc.). The content includes detailed bond issuance terms, trustee duties, annual operating and financial data of the issuer, use of raised funds, bondholder meetings, interest payments, credit rating updates, and other bond-related matters. The document is comprehensive and contains substantive financial data and operational details for the year 2023. It is not a simple announcement or a brief summary but a full report on the bond issuance and management for the year. This fits the category of a Capital/Financing Update (CAP) as it provides detailed information on the company's convertible bond issuance, management, and related financial data. It is not an Annual Report (10-K) as it focuses specifically on the convertible bond issuance and management rather than the entire company annual performance. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed substantive content rather than just an announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-06-13 Chinese
2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from 南京药石科技股份有限公司 regarding the implementation of the 2023 annual profit distribution (dividend) plan. It details the dividend amount per share, the record date, the ex-dividend date, and related adjustments such as convertible bond conversion price changes. It references the approval of the dividend plan at the 2023 annual general meeting and provides specifics on dividend payment methods and tax treatments. The document is not a full annual report or financial statement but a formal announcement of the dividend amount and payment details following shareholder approval. It fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders. The document length is 3380 characters, relatively short and focused solely on dividend distribution details, not a full report or financial analysis.
2024-06-06 Chinese
关于2023年年度权益分派调整可转债转股价格的公告
Capital/Financing Update Classification · 100% confidence The document is an announcement from Nanjing Yaoshi Technology Co., Ltd. regarding the adjustment of the conversion price of its convertible bonds following the 2023 dividend distribution. It details the previous and adjusted conversion prices, the basis for the adjustment, the formula used, and the effective date. The content focuses on a capital/financing update related to convertible bond terms and does not contain full financial statements or comprehensive financial performance data. The document length is short (1810 characters) and it is clearly an announcement about a financing-related adjustment rather than a full report or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-06-06 Chinese
关于实施权益分派期间药石转债暂停转股的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the suspension of convertible bond conversion rights during the equity distribution period. It includes details about the convertible bond code, suspension and resumption dates for conversion, and the formula for adjusting the conversion price based on equity changes. The document is short (1346 characters) and serves as a notification about bond conversion suspension related to equity distribution, not a full financial report or detailed financial data. It is an update on capital structure and financing terms related to convertible bonds, which fits the category of Capital/Financing Update (CAP).
2024-06-03 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.